BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 37696810)

  • 1. Zanubrutinib: past, present, and future.
    Tam CS; Muñoz JL; Seymour JF; Opat S
    Blood Cancer J; 2023 Sep; 13(1):141. PubMed ID: 37696810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zanubrutinib in lymphoproliferative disorders: a comprehensive review.
    Muñoz J; Wang Y; Jain P; Wang M
    Ther Adv Hematol; 2022; 13():20406207221093980. PubMed ID: 35651781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
    Geethakumari PR; Awan F
    Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.
    Sarosiek S; Sermer D; Branagan AR; Treon SP; Castillo JJ
    Expert Rev Anticancer Ther; 2022 May; 22(5):471-478. PubMed ID: 35404729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
    Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP
    Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions.
    Wolska-Washer A; Robak T
    Front Oncol; 2023; 13():1130595. PubMed ID: 37035197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
    Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
    Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia.
    Muñoz J; Paludo J; Sarosiek S; Castillo JJ
    Cells; 2022 Oct; 11(20):. PubMed ID: 36291152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zanubrutinib: a new BTK inhibitor for treatment of relapsed/refractory mantle cell lymphoma.
    Weaver AN; Jimeno A
    Drugs Today (Barc); 2020 Aug; 56(8):531-539. PubMed ID: 33025948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First.
    Deshpande A; Munoz J
    Ther Clin Risk Manag; 2022; 18():657-668. PubMed ID: 35770040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
    Hillmen P; Eichhorst B; Brown JR; Lamanna N; O'Brien SM; Tam CS; Qiu L; Kazmierczak M; Zhou K; Šimkovič M; Mayer J; Gillespie-Twardy A; Shadman M; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Österborg A; Yimer HA; Salmi T; Ji M; Yecies J; Idoine A; Wu K; Huang J; Jurczak W
    J Clin Oncol; 2023 Feb; 41(5):1035-1045. PubMed ID: 36395435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.
    Shirley M
    Target Oncol; 2022 Jan; 17(1):69-84. PubMed ID: 34905129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
    Tam CS; Ou YC; Trotman J; Opat S
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1329-1344. PubMed ID: 34491123
    [No Abstract]   [Full Text] [Related]  

  • 15. A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies.
    Moore DC; Thompson D
    J Adv Pract Oncol; 2021 May; 12(4):439-447. PubMed ID: 34123480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
    Lim KJC; Tam CS
    Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
    [No Abstract]   [Full Text] [Related]  

  • 17. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
    Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies.
    Muñoz J; Sarosiek S; Castillo JJ
    Oncologist; 2023 Apr; 28(4):309-318. PubMed ID: 36723874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
    Dreyling M; Tam CS; Wang M; Smith SD; Ladetto M; Huang H; Novotny W; Co M; Romano A; Holmgren E; Huang J; Gouill SL
    Future Oncol; 2021 Jan; 17(3):255-262. PubMed ID: 32985902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib in B lymphoid malignancies.
    Smith MR
    Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.